Last updated: 19 April 2024 at 8:06pm EST

Asif Ali Net Worth




The estimated Net Worth of Asif Ali is at least $2.46 Million dollars as of 18 April 2024. Mr Ali owns over 1,234 units of Protagonist Therapeutics Inc stock worth over $1,664,531 and over the last 3 years he sold PTGX stock worth over $795,295.

Mr Ali PTGX stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Protagonist Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 1,234 units of PTGX stock worth $30,986 on 18 April 2024.

The largest trade he's ever made was selling 24,187 units of Protagonist Therapeutics Inc stock on 29 February 2024 worth over $764,309. On average, Mr trades about 3,178 units every 6 days since 2022. As of 18 April 2024 he still owns at least 37,163 units of Protagonist Therapeutics Inc stock.

You can see the complete history of Mr Ali stock trades at the bottom of the page.





Mr. Asif Ali biography

Asif Ali is the Exec. VP & Chief Financial Officer at Protagonist Therapeutics Inc.



What's Mr Ali's mailing address?

Asif's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.

Insiders trading at Protagonist Therapeutics Inc

Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson..., and X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.



What does Protagonist Therapeutics Inc do?

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist



What does Protagonist Therapeutics Inc's logo look like?

Protagonist Therapeutics Inc logo

Complete history of Mr Ali stock trades at Protagonist Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Apr 2024 Asif Ali
Chief Financial Officer
Sale 1,234 $25.11 $30,986
18 Apr 2024
37,163
29 Feb 2024 Asif Ali
Chief Financial Officer
Sale 24,187 $31.60 $764,309
29 Feb 2024
38,397


Protagonist Therapeutics Inc executives and stock owners

Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include: